A potential first-in-class CD37 targeted therapy in Haematology
In this video we illustrate how Debio 1562M, a next generation antibody-drug conjugate (ADC) directed against CD37, internalizes B-cells and triggers tumor regression through the release of eight molecules of a DM1 derivative inhibiting tubulin binding.
Next generation ADC, Debio 1562M pre-clinical update
Dr. Lisa Ivanschitz, Associate Principal Scientist at Debiopharm
In this interview, Dr. Lisa Ivanschitz unveils recent preclinical data supporting the potential of Debio 1562M as a powerful biologic to treat hematological tumors like Acute Myeloid Leukemia (AML) and Myelodysplastic syndrome (MDS)
Discover the latest Debio1562M preclinical results
Here, we demonstrate that CD37 is broadly expressed in diverse AML and MDS models, including patient samples. Debio 1562M, a new CD37-targeting ADC, is efficiently internalized in these models, to a similar extent as in healthy or malignant B cells.
Leveraging the Power of Antibody-Drug Conjugates
ADCs are cutting-edge oncology therapeutics that combine three components: a monoclonal antibody, a linker and one or more potent cytotoxic payload. These targeted compounds identify and dock onto specific antigens on cancer cell surfaces and promote targeted delivery of toxic payloads to antigen-expressing cancer cells. This modality improves therapeutic effectiveness while diminishing systemic toxicity and side effects typically associated with conventional cancer treatments.
Our ADC portfolio consists of carefully selected targets with 1st-in-class or best-in-class potential, including Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) and Myelodysplastic syndromes (MDS) and Debio 0532, an HER3-targeted ADC for solid tumors. Key partnerships also comprise options to in-license bispecific antibodies targeting HER2-HER3 and HER3-EGFR along with other undisclosed targets. Our ADCs are designed with MultiLink™ proprietary cleavable linker technology, allowing both high DAR and high stability and are being developed with smart payload choices. Debio 1562M, with a novel DM1 derivative payload, represents our most advanced program expected to reach the clinic in H2 2025. We are continuing to invest in our ADC platform, exploring potential game changing technologies such as novel and dual payloads or degraders, leveraging our solid development experience to accelerate ADC products to patients.
